Clinuvel Pharmaceuticals Limited (ASX:CUV): FY26 Profit, SCENESSE and Pipeline Plans

Aditi Sarkar

02 November 2026 06:13 PM AEDT

Clinuvel Pharmaceuticals Limited (ASX:CUV): FY26 Profit, SCENESSE and Pipeline Plans

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue excluding interest and other income was AUD 94.0 million.
FY26 net profit after tax was AUD 33.9 million.
The company reported AUD 252.1 million of cash reserves at June-end.
Clinical development continued in vitiligo and other indications.

Clinuvel Pharmaceuticals Limited (ASX:CUV) commercialises and develops treatments for selected genetic and dermatological disorders. Its shares closed at AUD 7.09 on 2 November 2026. Recent 2026 company disclosures cover financial performance, operating developments and the work ahead. The relevant Business measures vary with its products, customers and funding model.

Photomedicine and Commercial Operations

Clinuvel Pharmaceuticals Limited (ASX:CUV) develops and commercialises therapies for selected genetic, metabolic and dermatological conditions. Its commercial product SCENESSE is used for eligible adults with erythropoietic protoporphyria, a disorder involving severe light sensitivity. The company also pursues programs addressing pigmentary and other disorders. Commercial treatment access depends on regulatory authorisations, specialist treatment centres, reimbursement arrangements and patient eligibility. Drug Development and planned product Diversification require clinical and regulatory investment. Information in company filings should be read by reporting period and by accounting definition. A revenue figure can describe services delivered, whereas cash receipts reflect the timing of customer payments and other movements. These measures answer different questions about the business.

2026 Commercial and Clinical Milestones

During 2026, Clinuvel Pharmaceuticals Limited (ASX:CUV) reported Canadian regulatory clearance to market SCENESSE for eligible EPP patients. The company continued its vitiligo work and stated in its Annual Report that twelve CUV105 case reports had been presented at scientific conferences. It also described validation of a Manufacturing process for NEURACTHEL Instant and preparations for a European regulatory filing. In October 2026, the company announced a filing relating to that product. Regulatory submission is not the same as Marketing approval, and timelines for clinical studies and additional commercial launches remain subject to regulatory decisions and operational delivery. Comparisons with the previous corresponding reporting period are useful for identifying the direction of activity, but a single reporting period does not determine a future outcome. Management targets and guidance remain subject to operating conditions and subsequent company updates.

FY26 Revenue, Profit and Cash Position

Clinuvel Pharmaceuticals Limited (ASX:CUV) reported FY26 revenue from ordinary activities excluding interest and other income of AUD 94.0 million, down from AUD 95.0 million in FY25. Its financial summary recorded total revenue including interest and other income of AUD 101.2 million, compared with AUD 105.3 million. Net profit after tax was AUD 33.9 million, down from AUD 36.2 million. Reported expenses were AUD 53.5 million, while cash reserves rose to AUD 252.1 million from AUD 224.1 million. The company defines cash reserves as cash and cash equivalents plus term deposits; this is not interchangeable with cash generated by operating activities. Understanding that distinction is important when considering how trials, manufacturing work and commercial expansion are financed.

Research and Commercial Risks

Clinuvel Pharmaceuticals Limited (ASX:CUV) remains dependent on SCENESSE commercial sales while investing in therapies that require additional clinical evidence and regulatory review. Potential risks include pricing and reimbursement changes, product concentration, study delays, trial recruitment, manufacturing processes and launch execution. Expansion into additional territories requires treatment-centre capacity and compliance with local prescribing conditions. Future disclosures on patient treatment activity, CUV105 results, filing outcomes, expenditure and Operating Cash Flow will help assess whether development plans are being delivered within the company’s available financial resources.

Key Insights

Clinuvel Pharmaceuticals Limited (ASX:CUV) remained profitable in FY26 and reported higher cash reserves despite lower revenue and net profit. SCENESSE continues to underpin commercial operations while clinical and regulatory programs aim to broaden the portfolio. Cash deployment, treatment access and clinical milestones are the central indicators to monitor.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.